Skip to main
KMTS

KMTS Stock Forecast & Price Target

KMTS Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Kestra Medical Techs is projected to continue its strong growth trajectory through international expansion and innovation in their Cardiac Recovery System platform, anchored by the ASSURE device with low false alarm rates and high patient compliance. Led by an experienced CFO and with a Buy rating from analysts, Kestra aims to dominate the growing market for AEDs with its aggressive sales strategy and differentiated technology. With a projected target price of $32, investing in Kestra Medical could prove to be a lucrative opportunity for investors in the long-term.

Bears say

Kestra Medical Techs is currently trading at a high valuation compared to the aggregate Small-Cap MedTech universe, and we believe this premium is not justified given the high level of risk and lack of profitability in the company. While the wearable technology for detecting and treating cardiovascular disease is promising, we have concerns about competition, clinical execution, and reimbursement decisions. Additionally, the current high valuation makes it difficult to justify an investment in Kestra Medical Techs at this time.

KMTS has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kestra Medical Technologies Inc (KMTS) Forecast

Analysts have given KMTS a Buy based on their latest research and market trends.

According to 5 analysts, KMTS has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kestra Medical Technologies Inc (KMTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.